ECM
ADCT icon

Endurant Capital Management’s ADC Therapeutics ADCT Stock Holding History

Endurant Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-58,967
Closed -$469K – 51
2022
Q2 		$469K Buy
+58,967
New +$558K 0.16% 46
2020
Q4 		– Sell
-12,000
Closed -$396K – 53
2020
Q3 		$396K Buy
12,000
+7,590
+172% +$329K 0.12% 58
2020
Q2 		$206K Buy
+4,410
New +$167K 0.01% 56

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GGH
GCM Grosvenor Holdings Chicago, Illinois $901M AUM 28.6% 1-Year Est. Return

Endurant Capital Management's ADCT Position: Q3 2022 in Review

Endurant Capital Management sold out of ADC Therapeutics (ADCT) in Q3 2022, closing a stake of 58,967 shares — an estimated $469K sold.

Endurant Capital Management first reported a position in ADCT in Q2 2020 and held it in 3 quarters. The position peaked at $469K in Q2 2022. 66 funds tracked by Wall St. Rank hold ADCT as of Q3 2022.

  • Endurant Capital Management reported no remaining ADC Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Endurant Capital Management sold 58,967 ADC Therapeutics shares in Q3 2022, an estimated $469K.
  • Endurant Capital Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 3 quarters.
  • Endurant Capital Management's ADC Therapeutics position peaked at $469K in Q2 2022.
  • 66 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2022.

Based on Endurant Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.